Phase 2 Study of MK-2206, an Allosteric Inhibitor of AKT, as Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer: A SWOG Cooperative Group Trial (S1005)
Explore this paper's citation graph
Summary
The AKT inhibitor MK‐2206 at a dose of 60 mg every other day was evaluated in gastric/gastroesophageal junction cancers.
- Type
- article
- Published
- 2015-03-30
- Cited by
- 78
- References
- 21
- OpenAlex
- https://openalex.org/W25827820
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:25915788
Keywords
Geography
References
- Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer
- Akt1/protein Kinase Bα is Involved in Gastric Cancer Progression and Cell Proliferation
- First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
- Mutational Analysis of AKT1, AKT2 and AKT3 Genes in Common Human Carcinomas
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- Capecitabine and oxaliplatin for advanced esophagogastric cancer.
- Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
- Akt inhibitors in clinical development for the treatment of cancer
- Chemotherapy for advanced gastric cancer.
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
- Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
- Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.
- A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Cited by
- Gastric cancer management: Kinases as a target therapy
- Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases.
- The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective.
- Evolving treatments for advanced gastric cancer: appraisal of the survival trend
- AKT in cancer: new molecular insights and advances in drug development
- Targeted therapies in gastric cancer and future perspectives.
- The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer
- How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
- Targeting leiomyomas with all‐trans‐retinoic acid at phosphoinositide 3‐kinase pathway suppression: Effective roles of β‐catenin and of signaling interactions
- Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.
- Gastric cancer: somatic genetics as a guide to therapy
- Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis
- Maximising the potential of AKT inhibitors as anti-cancer treatments
- Targeted therapies for gastric cancer: failures and hopes from clinical trials
- Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway.
- Akt as a target for cancer therapy: more is not always better (lessons from studies in mice)
- Curcuminoid EF24 enhances the anti‐tumour activity of Akt inhibitor MK‐2206 through ROS‐mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer
- AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells
- Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
- Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.
Related papers
No related papers recorded.